StockData

NewAmsterdam Pharma vs ProQR Therapeutics

NAMS and PRQR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NAMS and PRQR compare

ProQR Therapeutics grew revenue faster over the last twelve months (11.4% versus −88.9% for NewAmsterdam Pharma).

ProQR Therapeutics keeps more of each dollar of sales as profit, with a net margin of −229% compared with −3644% at NewAmsterdam Pharma.

ProQR Therapeutics scores higher on the StockData Score (7 against 6 for NewAmsterdam Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNAMSPRQR
Size and price
Share price$19.39$1.15
Change, 1 year−49.4%−47.0%
Change, 5 years98.1%−84.0%
Beta (5Y)1.572.58
Employees10059
StockData Score
Total score67 (better)
Valuation score00
Growth score02 (better)
Performance score12 (better)
Health score5 (better)3
Dividend score00
Growth
Revenue growth (TTM)−88.9%11.4% (better)
Profitability
Operating margin−3432%−233% (better)
Net margin−3644%−229% (better)
FCF margin−2018%−273% (better)
Return on equity−36.8% (better)−57.4%
Return on invested capital−1046%–
Financial health
Debt / equity0.000.06 (better)
Current ratio9.03 (better)3.49
Piotroski F-score3 (better)1
Ownership
Held by institutions–57.6%
Held by insiders22.0%37.8%
Insider net buying, 12 months−$63.0M$1.3M (better)

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.